Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) rose 3% during trading on Thursday . The stock traded as high as $19.60 and last traded at $19.57, with a volume of 406,208 shares traded. The stock had previously closed at $19.00.

AMPH has been the subject of several research analyst reports. Needham & Company LLC reduced their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. BMO Capital Markets initiated coverage on Amphastar Pharmaceuticals in a report on Tuesday, June 28th. They issued a “market perform” rating and a $17.00 price objective for the company. Jefferies Group lifted their price objective on Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $22.00 price objective on shares of Amphastar Pharmaceuticals in a report on Thursday, August 11th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $19.83.

The stock has a market capitalization of $878.51 million and a price-to-earnings ratio of 63.21. The stock’s 50 day moving average price is $17.22 and its 200-day moving average price is $14.10.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.22. The company had revenue of $68 million for the quarter, compared to analysts’ expectations of $62.10 million. The company’s revenue for the quarter was up 26.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.09) earnings per share. Analysts anticipate that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current year.

In related news, Director Stephen B. Shohet sold 48,375 shares of the company’s stock in a transaction on Tuesday, August 16th. The stock was sold at an average price of $18.24, for a total transaction of $882,360.00. Following the completion of the sale, the director now directly owns 28,653 shares in the company, valued at approximately $522,630.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 2,297 shares of the company’s stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $16.00, for a total value of $36,752.00. Following the sale, the chief financial officer now owns 66,949 shares of the company’s stock, valued at $1,071,184. The disclosure for this sale can be found here.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.